Alnylam Pharmaceuticals, Inc.

NASDAQ:ALNY

331.91 (USD) • At close July 3, 2025
Bedrijfsnaam Alnylam Pharmaceuticals, Inc.
Symbool ALNY
Munteenheid USD
Prijs 331.91
Beurswaarde 43,277,081,080
Dividendpercentage 0%
52-weken bereik 205.87 - 333.7
Industrie Biotechnology
Sector Healthcare
CEO Dr. Yvonne L. Greenstreet M.B.A., MBA, MBChB
Website https://www.alnylam.com

An error occurred while fetching data.

Over Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex

Vergelijkbare Aandelen

Insulet Corporation logo

Insulet Corporation

PODD

301.05 USD

BioMarin Pharmaceutical Inc. logo

BioMarin Pharmaceutical Inc.

BMRN

57.5 USD

Viatris Inc. logo

Viatris Inc.

VTRS

9.32 USD

Bio-Techne Corporation logo

Bio-Techne Corporation

TECH

53.14 USD

Incyte Corporation logo

Incyte Corporation

INCY

68.45 USD

ICON Public Limited Company logo

ICON Public Limited Company

ICLR

150.1 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)